Roth Capital analyst Boobalan Pachaiyappan lowered the firm’s price target on Cingulate (CING) to $16 from $17 and keeps a Buy rating on the shares, with the firm noting it caught up with Cingulate management to discuss Q3 results. At a high level, the company is ratcheting up its CTx-1301 U.S. pre-commercialization efforts through its Indegene partnership, the analyst tells investors in a research note. The firm expects CTx-1301 approval by May 31, 2026.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CING:
- Cingulate Inc.’s Promising Market Position Bolstered by Strategic Partnerships and Innovative ADHD Treatment
- CING Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Cingulate Inc. Reports Q3 2025 Financial Results
- Cingulate reports Q3 net loss ($7.3M) vs ($4.1M) last year
- Cingulate Inc Signs Note Purchase Agreement with Avondale